A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors

This study is testing a new type of immune cell therapy — called CAR-T cells — for people with hard-to-treat blood cancers like leukemia, lymphoma, or multiple myeloma that have come back or stopped responding to standard treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a B-cell blood cancer (such as leukemia, DLBCL, follicular lymphoma, mantle cell lymphoma, or multiple myeloma) - Your cancer has returned or stopped responding to at least one round of standard therapy - Your liver, kidney, and heart function are within acceptable ranges - You are in reasonably good overall health (able to carry out basic daily activities) - At least 2 weeks have passed since your last cancer treatment **You may NOT be eligible if...** - You have active graft-versus-host disease after a previous stem cell transplant - You have a severe active infection or immune deficiency - You have moderate to severe heart failure - You have epilepsy or brain/spinal cord disease - Your lymphoma has spread to the brain, lungs, or gut - You are pregnant or breastfeeding - You have another active cancer (with limited exceptions) Talk to your doctor to see if this trial is right for you.